‘MSD Korea proposed unprecedented offer for Keytruda reimbursement’

Korea Biomedical Review

12 July 2021 - MSD’s Keytruda (pembrolizumab), immunotherapy for lung cancer, is the company’s flagship item that sold $14.38 billion worldwide last year.

However, MSD Korea is struggling with limited reimbursement for Keytruda in Korea.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , Korea